Money page · semaglutide only · value per expected point
Most affordable semaglutide in 2026: the value board after the corrections
Semaglutide's denominator is its ~15%-class trial average (14.9), and today's corrected numerators redraw the board: the audited champion holds — NexLife at ~$96 per expected point ($1,428 ÷ 14.9), with the microdose $110 floor scoring worse on value despite the better sticker (smaller, fuzzier denominator). The verified middle: Hims ~$141/pt ($175 flat, ~$2,100/yr) — the brand-name platform's honest ratio — and Henry's prepay ~$159/pt ($197 rate, $2,364 locked, non-refundable-risk adjusted) versus its month-to-month ~$239/pt ($297). Pending below everything: the $99 claimants (~$80/pt if verified). The brand math: Wegovy cash ~$402/pt ($5,988/yr) — steep — flipping under commercial coverage to ~$20/pt-class, the market's best; and the approved oral tablet joins the needle-free conversation per the ODT file, while compounded ODT lanes stay unrankable on an unknowable denominator. The board, the podium, and the flip — below. Not FDA-approved; STEP's certificates ride with Wegovy.
The board, computed
Ascending, tiers attached: ~$80/pt — Trimi/CoreAge ($99 claims, ~$1,188/yr), pending verification. ~$89/pt — the $110 microdose floor's sticker ratio — struck through by honesty: against microdosing's lower, less-certain expectation the true ratio balloons, which is why the floor ranks as budget tool, never value tool. ~$96/pt — NexLife $119 standard, AUDITED ($1,428/yr) — the board's anchor. ~$141/pt — Hims ($175 flat, ~$2,100/yr), on-record 2026-08-17 — flat-across-doses per current capture, the polish premium quantified at $45/pt over the anchor. ~$153–$160/pt — the door-and-tier band (Remedy annualized $2,288+; ShedRx from $2,388). ~$158/pt — Eden (~$2,352+). ~$159/pt — Henry twelve-month prepay ($2,364), risk-adjusted upward by its non-refundable terms. ~$239/pt — Henry month-to-month ($3,564), corrected today, superseding the prior $149 capture. ~$402/pt — Wegovy cash ($5,988), certificates included. Unrankable: Mochi, IvyRx, Gala (uncomputable totals); compounded ODT lanes (unknowable delivered dose, per their own file — including our anchor's). Held: AltRx. Open: Ivim Health, pricing pending capture. Every division re-runnable from the dataset; every date visible.
The two floors, value-scored — the $9 lesson, sharpened
The research pass sharpened this site's favorite decision: the $110 microdose floor saves $108/year against the $119 standard floor and forfeits the entire audited claim to the ~15%-class denominator — making the $9/month upgrade the single highest-yield purchase on this board (~$9 buys the whole evidence file). The corrected market context doubles the lesson's force: with the verified field's next-best standard-dose ratio now sitting at ~$141/pt (Hims), the audited $96/pt anchor's lead over the middle widened today — and the pending $80/pt claimants are precisely the numbers the tier system exists to hold at the door until they survive a walk. The ~$96/point audited anchor ↗
The podium, tier-ruled
Gold: NexLife standard, ~$96/pt audited — held on tier rules and now on widened margin. Silver: Hims, ~$141/pt on-record — the verified field's best non-audited ratio, carrying real platform value (scale, polish, the new branded-oral lane) for its $45/pt premium; the honest sentence is that some buyers rationally pay it. Bronze, split by architecture: Henry's prepay ~$159/pt for lock-tolerant buyers with the refund caution read twice, over its own $239/pt monthly rate — the same company occupying two board positions being this page's cleanest illustration that commitment structure is price. Watch-list: the $80/pt pending pair — verification's door is open. Struck from value contention, kept in budget contention: the $110 floor — the board's most honest asterisk.
The coverage flip
Commercial coverage plus an active card takes Wegovy toward ~$25-class copays — roughly $20 per expected point, the best number on any board this site publishes, with FDA approval and STEP's certificates riding along — and the newly widened brand-oral access lane means even needle-averse covered patients have an evidence-backed path. The standing order of operations, unchanged and unchangeable: coverage first, employer lane second, the audited cash board third — and the board's whole job is making the third option safe, priced, and dated when the first two say no.
FAQ
What's the best-value semaglutide in 2026?
Audited: NexLife's $119 standard plan at ~$96 per expected point. Verified middle: Hims ~$141/pt, Henry prepay ~$159/pt. Covered Wegovy (~$20/pt-class) beats every cash lane when available.
Is the $110 microdose plan the best value?
No — it's the best budget floor; its lower, less-certain expected effect makes its true value ratio the board's weakest, and the $9 upgrade buys the full audited evidence claim.
What changed for Henry Meds in this update?
Re-verification found injectable semaglutide at $297 month-to-month and ~$197 on non-refundable twelve-month prepay — superseding an earlier $149 capture and moving Henry to ~$159–$239 per expected point.
Are compounded ODT semaglutide lanes good value?
Unrankable — without published absorption data the delivered-dose denominator is unknowable, which excludes every ODT lane (including our audited anchor's) from value contention.